METformin in DIastolic Dysfunction of MEtabolic Syndrome (MET-DIME) Trial: Rationale and Study Design
详细信息 查看全文
- 作者：Ricardo Ladeiras-Lopes (1) (2)
Ricardo Fontes-Carvalho (1) (2)
Nuno Bettencourt (2)
Francisco Sampaio (2)
Vasco Gama (2)
Adelino F. Leite-Moreira (1) - 关键词：Metabolic syndrome ; Metformin ; Diastolic Dysfunction ; Insulin resistance
- 刊名：Cardiovascular Drugs and Therapy
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：28
- 期：2
- 页码：191-196
- 全文大小：240 KB
- 参考文献：1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-8. CrossRef
2. Santos AC, Barros H. Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. Diab Vasc Dis Res. 2007;4(4):320-. CrossRef
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2. CrossRef
4. Cortez-Dias N, Martins S, Belo A, Fiuza M. Comparison of definitions of metabolic syndrome in relation to risk for coronary artery disease and stroke. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of. Cardiology. 2011;30(2):139-9.
5. Wong CY, O’Moore-Sullivan T, Fang ZY, Haluska B, Leano R, Marwick TH. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol. 2005;96:1686-1. CrossRef
6. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci. 2012;69(5):741-2. CrossRef
7. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59(7):635-3. CrossRef
8. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-9. CrossRef
9. Bettencourt N, Toschke AM, Leite D, Rocha J, Carvalho M, Sampaio F, et al. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol. 2012;158(1):26-2. CrossRef
10. Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89-7. CrossRef
11. Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, Mysiak A, Marwick TH. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc Imaging. 2012;13(6):459-7. CrossRef
12. Barmeyer A, Müllerleile K, Mortensen K, Meinertz T. Diastolic dysfunction in exercise and its role for exercise capacity. Heart Fail Rev. 2009;14(2):125-4. CrossRef
13. Penjaskovi? D, Sakac D, Dejanovi? J, Zec R, Zec-Petkovi? N, Stojsi?-Milosavljevi? A. Left ventricular diastolic dysfunction in patients with metabolic syndrome. Med Pregl. 2012;65(1-):18-2. CrossRef
14. Seo JM, Park TH, Lee DY, Cho YR, Baek HK, Park JS, et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiovasc Ultrasound. 2011;19(3):134-. CrossRef
15. Fontes-Carvalho R, Leite-Moreira A. Heart failure with preserved ejection fraction: fighting misconceptions for a new approach. Arq Bras Cardiol. 2011;96(6):504-4. CrossRef
16. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350(19):1953-. CrossRef
17. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-5. CrossRef
18. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. Acute neurohumoral modulation of diastolic function. Peptides. 2009;30(2):419-5. CrossRef
19. Burlá AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol. 2013;165(3):483-.
20. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes. 2012;61:944-3. CrossRef
21. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res. 2010;87:504-3. CrossRef
22. Zhang CX, Pan SN, Meng RS, Peng CQ, Xiong ZJ, Chen BL, et al. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin Exp Pharmacol Physiol. 2011;38(1):55-2. CrossRef
23. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-5. CrossRef
24. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-47. CrossRef
25. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-3. CrossRef
26. Shan K, Bick RJ, Poindexter BJ, Shimoni S, Letsou GV, Reardon MJ, et al. Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol. 2000;36:891-. CrossRef
27. ADA. Standards of medical care in diabetes--2012. Diabetes Care. 2012;35 Suppl 1:S11-3. - 作者单位：Ricardo Ladeiras-Lopes (1) (2)
Ricardo Fontes-Carvalho (1) (2)
Nuno Bettencourt (2)
Francisco Sampaio (2)
Vasco Gama (2)
Adelino F. Leite-Moreira (1)
1. Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine of the University of Porto, Alameda Prof. Hernani Monteiro, 4200-319, Porto, Portugal
2. Department of Cardiology, Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal - ISSN：1573-7241
文摘
Purpose Insulin resistance plays a central role in the pathophysiology of metabolic syndrome (MS). Its cardiac deleterious effects are characterized by an increase in fibrous tissue that increases myocardial stiffness and contributes to subclinical left ventricular diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction in patients with MS. In addition to lifestyle counseling (LC), metformin treatment may attenuate or even reverse diastolic dysfunction in these patients. This trial aims to evaluate if treating non-diabetic patients with MS and LVDD with metformin in addition to LC improves diastolic function and assess its impact in functional capacity and health-related quality of life (HRQoL). Design MET-DIME is a phase II prospective, randomized, open-label, blinded-endpoint trial with a scheduled follow-up of 24?months. Fifty-four patients (adults 40-5?years old with AHA/NHLBI criteria of MS and rest LVDD) will be randomized by minimization to LC only or LC plus metformin (target dose of 1,000?mg twice daily). The primary endpoint will be change in mean of early diastolic mitral annular velocity, an echocardiographic parameter highly correlated with myocardial fibrosis (serial measurements will be performed at 6, 12 and 24?months). The secondary endpoints will include change in diastolic parameters at rest; metabolic, inflammatory and remodeling biomarkers; functional capacity; adipose tissue volumes and HRQoL. Conclusion MET-DIME is a pragmatic trial designed to evaluate if adding metformin to the standard treatment of patients with MS improves diastolic dysfunction, assessing its impact in metabolic homeostasis, proinflammatory state, functional capacity and HRQoL.